Truist Financial Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
Truist Financial analyst Joon Lee maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today. The company’s shares closed ...
Axsome Therapeutics price target raised to $195 from $137 at Mizuho
Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...
Axsome stock target raised to $190 on Teva litigation resolution
TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on ...